linjc16/ctgov huggingface dataset:
Establish the Caring Model of Children With Chronic Kidney Disease and End-stage Renal Disease: To Set up Childhood Glomerular Filtration Rate (GFR) Formula in Taiwan

Study Overview
=================
Brief Summary
-----------------
Inulin's usefulness as a diagnostic agent is based on the method of its elimination from the body. Inulin is biologically inert, unbound by plasma proteins, freely filtered at the glomerulus, and is neither reabsorbed, metabolized nor secreted by the kidneys. It is excreted almost entirely by glomerular filtration. Inulin clearance is considered to be identical to glomerular filtration rate (GFR).

Conditions
-----------------
Chronic Kidney Disease, End-Stage Renal Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Main inclusion criteria: Pediatric OPD, age < 18 y/o. Main exclusion criteria: Acute renal failure, edema, muscular dystrophy, pleural effusion, ascites, malnutrition, neurogenic bladder, heart failure and ketoacidosis. And taken cimetidine or trimethoprim, and accepted renal replacement therapy.

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| a single-group study<br>Pediatric OPD, age < 18 y/o. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Inulin, childhood GFR formula
The Impact of Docosahexaenoic Acid on the Prevention of Necrotizing Enterocolitis in Preterm Neonates

Study Overview
=================
Brief Summary
-----------------
The study will assess the efficacy of Docosahexaenoic Acid in reducing the incidence of necrotizing enterocolitis in premature infants.

Detailed Description
-----------------
The efficacy of Docosahexaenoic Acid in reducing the incidence of necrotizing enterocolitis in preterm neonates will be evalutaed through measuring its immune-modulatory effect on proinflammatory cytokines.

Official Title
-----------------
A Clinical Study on the Impact of Docosahexaenoic Acid on the Prevention of Necrotizing Enterocolitis in Preterm Neonates

Conditions
-----------------
Necrotizing Enterocolitis

Intervention / Treatment
-----------------
* Dietary Supplement: Docosahexaenoic Acid
* Other: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preterm neonates having a gestational age equal or less than 34 weeks at birth. Weight (less than or equal 1.500 KG) Clinically stable to begin enteral feeding Exclusion Criteria: Persistent bleeding at any level. Receiving medication to avoid coagulation. Persistent vomiting. Gastrointestinal malformations. Mother taking Omega-3 supplements and planning to breastfeed.

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 3 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Docosahexaenoic Acid Group<br>participants will recieve 100 milligrams of Docosahexaenoic Acid per day for 14 days | Dietary Supplement: Docosahexaenoic Acid<br>* 100 milligrams of Docosahexaenoic Acid<br>|
| Placebo Comparator: Control Group<br>participants will recieve placebo | Other: placebo<br>* placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of Docosahexaenoic Acid in reducing the incidence of Necrotizing Enterocolitis in premature infants. | Monitoring the change in the serum levels of Interleukin-1 beta | 10 days |
Subcutaneous Closed-Suction Drainage Affects Surgical Wounds Healing in Lower Gastrointestinal Open Surgery: a Randomized Controlled Study

Study Overview
=================
Brief Summary
-----------------
This is a single-center, randomized controlled trial to evaluate whether subcutaneous closed-suction drainage would decrease the incidence of poor surgical site healing in lower gastrointestinal open surgery. The independent risk factors of the incidence of poor surgical wounds healing in lower gastrointestinal open surgery will be analyzed.

Official Title
-----------------
Subcutaneous Closed-Suction Drainage Affects Surgical Wounds Healing in Lower Gastrointestinal Open Surgery: a Randomized Controlled Study

Conditions
-----------------
All Diseases That Require Gastrointestinal Open Surgery

Intervention / Treatment
-----------------
* Device: Subcutaneous closed-suction drainage device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 18-85 years old, male or female all patients underwent lower gastrointestinal surgery: the digestive tract below Treitz ligament was called lower gastrointestinal tract, including jejunum, ileum, ileocecal part and colorectal open surgery (instead of laparoscopic) required willing participated in clinical verification and signed informed consent. Exclusion Criteria: laparoscopic surgery upper gastrointestinal surgery (esophagus, stomach, duodenum and hepatobiliary pancreas) simple appendectomy / total appendectomy hernia surgery and intestinal obstruction surgery without intestinal resection infection of incision site before operation pregnant women expected death within 1 month after operation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental group<br>the closed-suction drainage device will be placed subcutaneously when closing the incision | Device: Subcutaneous closed-suction drainage device<br>* This subcutaneous closed-suction drainage device was designed to be placed subcutaneously when surgeons have completed all intra-abdominal operations and are about to suture subcutaneous layer and skin<br>|
| No Intervention: Control group<br>the closed-suction drainage device will not be placed subcutaneously when closing the incision | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of poor healing of incisions |  | Within 30 days after surgery |
Study to Investigate the Added Value of a Rehabilitation Brace in the Treatment at Home After a Fracture of the Ankle

Study Overview
=================
Brief Summary
-----------------
Comparison between immobilisation by a plaster and a rehabilitation brace for the treatment of a fracture of the ankle

Official Title
-----------------
Study to Investigate the Added Value of a Rehabilitation Brace in the Treatment at Home After a Fracture of the Ankle

Conditions
-----------------
Fracture of the Ankle

Intervention / Treatment
-----------------
* Device: Use of a rehabilitation brace instead of a plaster


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fracture of the ankle Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Use of a rehabilitation brace instead of a plaster|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mobility of the ankle |  |  |
Correlation of Muscle Ultrasound Measures (2D and 3D) With Biphotonic X-ray Absorptiometry in Oldest Old Patients.

Study Overview
=================
Brief Summary
-----------------
The sarcopenia diagnosis is based on the muscle mass and on impaired physical performance. The emerging field of ultrasound assessment of muscle mass in older patients is based on 2d parameters with prediction equations for muscle mass. For the moment, validation of prediction equations in older adults with varying function and health is lacking. The study aims to evaluate correlation of muscle mass between 3D muscle mass measurement and DXA, in order to dispense with the prediction equation.

Detailed Description
-----------------
Older patients who agree to participate to the study will undergo 3D ultrasound muscle mass measurement, 2D panoramic mode muscle mass measurement and biphotonic X-ray absorptiometry assessment. Correlation analysis will be done with the different measurement.

Official Title
-----------------
Correlation of Muscle Ultrasound Measures (2D and 3D) With Biphotonic X-ray Absorptiometry in Oldest Old Patients.

Conditions
-----------------
Assessment, Self, Muscle Atrophy, Ultrasound Therapy; Complications, Aging

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 75 years old Osteoporosis diagnosis confirmed by Dual-energy X-ray Absorptiometry Exclusion Criteria: Neurocognitive disorders preventing the expression of informed consent Patients who cannot undergo an examination in a static position Lack of a measurement site (muscle resection or amputation) Any state of dehydration or water inflation Patient with legal protection measure

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|No intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3D Correlation between muscle volume measured by 3D ultrasound and standard method : DXA results | Correlation between muscle volume measured by 3D ultrasound and standard method : DXA results | 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 2D correlation between muscle volume measured by 2D ultrasound and standard method : DXA results | Correlation between muscle volume measured by 2D ultrasound and standard method : DXA results | 1 week |
ME/CFS, Hypermobility and Craniocervical Obstructions

Study Overview
=================
Brief Summary
-----------------
A retrospective study on clinical and radiological findings in ME/CFS

Official Title
-----------------
Hypermobility and Obstructions in the Craniocervical Region Among Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Conditions
-----------------
Chronic Fatigue Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients at a multidisciplinary specialist clinic accepting to participate Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of cervical obstruction and other MRI findings | Findings as disc bulging, disc hernias, chiari malformations | 1990-2020 | 
| Prevalence of hypermobility | Measured as Beighton score and other signs of Ehlers Danlos syndrome (EDS) variations | 1990-2020 |
Spinal Clearance Study: Expediting the Spinal Clearance Process in the Major Trauma Patient

Study Overview
=================
Brief Summary
-----------------
The Alfred Hospital receives approximately 40% of the major trauma patients in Victoria, all of whom are at risk for spinal injuries. The potential for spinal injuries necessitates the undertaking of appropriate spinal investigations, and a delay in the completion of these investigations exposes the patient to the risk of a missed diagnosis of spinal instability and of complications of immobility; the potential spinal patient is required to wear a neck collar and be nursed lying flat whilst awaiting the completion and the appropriate documentation of spinal X-ray investigations. The purpose of this study is to identify the issues causing a delay in the process of the completion of the appropriate spinal investigations and the documentation of the results. The outcome of the proposed research will be the development of a clinical management protocol to expedite the process, with the aim of optimising patient care and reducing complications.

Official Title
-----------------
Optimisation of Patient Management Through Expediting the Spinal Clearance Process in the Major Trauma Patient

Conditions
-----------------
Multiple Trauma, Traumatic Brain Injury, Spinal Injuries

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major trauma patients Exclusion Criteria: Patients not subjected to spinal position restrictions on admission Patients deceased prior to spinal clearance Patients transferred to another centre prior to spinal clearance
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Trauma Patients<br>Major trauma patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cervical spine injury, multiple trauma
Prevention Of Recurrence Of Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).

Official Title
-----------------
A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of SB 207266 in Patients With Symptomatic Persistent Atrial Fibrillation (AF)

Conditions
-----------------
Fibrillation, Atrial

Intervention / Treatment
-----------------
* Drug: SB-207266
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptomatic persistent atrial fibrillation requiring DC cardioversion. Duration of AF >48 hrs. <6 months Exclusion Criteria: Concomitant Class I and/or III anti-arrhythmic drugs. Amiodarone treatment within 3 months of the study. Other inclusion or exclusion criteria to be determined by the physician and study sponsor.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br>Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or placebo | Drug: SB-207266<br>* White, oval, biconvex tablets containing either 10mg, 25mg or 40mg<br>|
| Placebo Comparator: Arm 2<br>Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or Placebo | Other: Placebo<br>* Placebo to match SB-207266<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time-to-first symptomatic AF (atrial fibrillation) |  | Up to 26 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to first symptomatic or detected asymptomatic AF; spontaneous reversion to sinus rhythm prior to cardioversion |  | Up to 26 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
symptomatic atrial fibrillation, persistent atrial fibrillation
Real Life Automatic Atrial Capture Device Control

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to verify the effectiveness of the new ACAP ® Confirm algorithm in the automatic management of atrial capture.

Official Title
-----------------
Registry on Automatic Algorhitm on Atrial Capture: REAL ACap Registry

Conditions
-----------------
Sinus Bradycardia, Sinus Node Disease, Atrio-ventricular Block, Heart Failure

Intervention / Treatment
-----------------
* Device: Pacemaker, ICD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients had undergone first implantation or device replacement with a Medical device (PM, ICD, CRT-P, CRT-D) endowed with ACAP Confirm ® algorithm features between May 2011 and March 2012 Exclusion Criteria: Atrial fibrillation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years


Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Pacemaker, ICD|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The main objective of this study is to verify the effectiveness of the new ACAP Confirm ® algorithm in management of atrial capture in both new implants and patients undergoing device replacements with different manufactures atrial leads. |  | 6 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship with pulse width |  | 6 Months | 
| Clinical equivalence of automatic and manual thresholds tests results. |  | 6 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ACAP, Automatic Algorithm
Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids

Study Overview
=================
Brief Summary
-----------------
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of cancer. Despite advances in the understanding of the mechanisms underlying PDAC pathogenesis, the impact on patient benefit is lagging. As a result, new model systems are being developed and used to fill this gap with the hope of translation into improved diagnostics and therapeutics. Organoids represent a powerful tool for research with the capacity to be applied to many key aspects of pancreatic tissue pathology. 3D organoids can be generated from endoscopic fine-needle aspiration or fine needle biopsy samples. In this study, we will evaluate and compare the growth rate of pancreatic cancer patient-derived organoids generated from matched fine needle Aspirations (FNA) and fine needle biopsies (FNB).

Official Title
-----------------
Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids Generated From Matched Fine Needle Aspirations (FNA) and Fine Needle Biopsies (FNB)

Conditions
-----------------
Pancreas Cancer

Intervention / Treatment
-----------------
* Procedure: FNA, FNB


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with indication for EUS-guided FNA or FNB of a suspected pancreatic malignancy Exclusion Criteria: < 18 years patients unable to give consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FNA, FNB<br> | Procedure: FNA, FNB<br>* Endoscopic ultrasound guided fine needle aspiration, Endoscopic ultrasound guided fine needle biopsy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Growth rate | Organoid growth will be determined using bi-weekly measurements by phase-contrast microscopy calculating the total organoid area as well as individual organoid size. In addition, growth rates will be determined using the cell glow assay (Promega) over a time-course of 4 days. Furthermore, the mean passaging time will be calculated after 5 passages. | 4 days |
Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology

Study Overview
=================
Brief Summary
-----------------
Severe SARS-CoV-2 infection, responsible of COVID-19, is accompanied by many venous thromboembolic events. Antithrombotic treatment is the cornerstone of management of many neurovascular diseases (NVDs) and the benefit-risk ratio is crucial to avoid hemorrhagic complications. Therefore, in non-severe COVID-19 patients affected by NVDs, the diagnostic of deep venous thrombosis (DVT) is challenging. Using bedside Doppler ultrasonography (DUS) of lower limbs, this study investigated the rates of DVT in these patients in stroke unit.

Official Title
-----------------
High Prevalence of Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology

Conditions
-----------------
Deep Venous Thrombosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Age>18 years COVID-19 confirmed with RT-PCER and/or chest CT-scan Acute neurovascular disease defined as transient ischemic attack or acute ischemic stroke or venous cerebral thrombosis or hemorrhagic stroke. Exclusion criteria: age<18 Other neurovascular diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of cumulated deep venous thrombosis among the hospitalization |  | Day 7 after admisssion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non-severe COVID-19, neurovascular diseases, Doppler ultrasound, Deep venous thrombosis, Covid-19, SARS-CoV-2